To more directly assess the role of B2M and IGFBP4 in mediating hormone therapy effects on CHD and stroke, respectively, we are currently carrying out ELISA analyses of baseline and 1-year plasma samples in the WHI hormone therapy trials. The gene discussed is IGFBP4; the disease is coronary artery disorder.